Access the full text.
Sign up today, get DeepDyve free for 14 days.
D. Ellis, S. Dissanayake, D. Mcguire, S. Charapata, P. Staats, M. Wallace, G. Grove, P. Vercruysse (2008)
Continuous Intrathecal Infusion of Ziconotide for Treatment of Chronic Malignant and Nonmalignant Pain Over 12 Months: A Prospective, Open‐label StudyNeuromodulation: Technology at the Neural Interface, 11
I. Veizi, Salim Hayek, S. Narouze, Jason Pope, N. Mekhail (2016)
SPINE SECTION Original Research Article Combination of Intrathecal Opioids with Bupivacaine Attenuates Opioid Dose Escalation in Chronic Noncancer Pain Patients
Marieke Everdingen, J. Rijke, A. Kessels, H. Schouten, M. Kleef, J. Patijn (2007)
Prevalence of pain in patients with cancer: a systematic review of the past 40 years.Annals of oncology : official journal of the European Society for Medical Oncology, 18 9
P. Tumber, D. Fitzgibbon (1998)
The control of severe cancer pain by continuous intrathecal infusion and patient controlled intrathecal analgesia with morphine, bupivacaine and clonidinePain, 78
R. Dongen, B. Crul, J. Egmond (1999)
Intrathecal coadministration of bupivacaine diminishes morphine dose progression during long-term intrathecal infusion in cancer patients.The Clinical journal of pain, 15 3
C. Cleeland (1991)
Research in cancer pain. What we know and what we need to knowCancer, 67
C. Smyth, N. Ahmadzai, Jason Wentzell, Ashley Pardoe, A. Tse, Tiffany Nguyen, Yvette Goddard, S. Nair, P. Poulin, B. Skidmore, M. Ansari (2015)
Intrathecal Analgesia for Chronic Refractory Pain: Current and Future ProspectsDrugs, 75
K. Follett, K. Burchiel, T. Deer, S. Dupen, J. Prager, Michael Turner, R. Coffey (2003)
Prevention of Intrathecal Drug Delivery Catheter‐Related ComplicationsNeuromodulation: Technology at the Neural Interface, 6
P. Sloan, R. Melzack (1999)
Long-term patterns of morphine dosage and pain intensity among cancer patients.The Hospice journal, 14 2
C. Pert, S. Snyder (1973)
Opiate Receptor: Demonstration in Nervous TissueScience, 179
Pain Med
G. Kurita, K. Benthien, K. Benthien, Mie Nordly, Mie Nordly, S. Mercadante, P. Klepstad, P. Sjøgren, P. Sjøgren (2015)
The evidence of neuraxial administration of analgesics for cancer‐related pain: a systematic reviewActa Anaesthesiologica Scandinavica, 59
Thomas Smith, P. Staats, T. Deer, L. Stearns, R. Rauck, R. Boortz-Marx, E. Buchser, E. Catalá, D. Bryce, P. Coyne, G. Pool (2002)
Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 19
Ching-Yue Yang, Chih-Shung Wong, Jang-Yang Chang, S. Ho (1996)
Intrathecal ketamine reduces morphine requirements in patients with terminal cancer painCanadian Journal of Anaesthesia, 43
D. Atkins, D. Best, P. Briss, M. Eccles, Y. Falck-Ytter, S. Flottorp, G. Guyatt, R. Harbour, M. Haugh, D. Henry, S. Hill, Roman Jaeschke, G. Leng, A. Liberati, N. Magrini, J. Mason, P. Middleton, J. Mrukowicz, Dianne O'Connell, A. Oxman, B. Phillips, H. Schünemann, T. Edejer, H. Varonen, G. Vist, John Williams, S. Zaza (2004)
Grading quality of evidence and strength of recommendationsBMJ : British Medical Journal, 328
J. Wang, L. Nauss, John Thomas (1979)
Pain relief by intrathecally applied morphine in man.Anesthesiology, 50 2
Support Care Cancer, 18
J. Eisenach, S. Dupen, M. Dubois, R. Miguel, D. Allin (1995)
Epidural clonidine analgesia for intractable cancer painPain, 61
Oncol Econ, 1
R. Dongen, B. Crul, M. Bock (1993)
Long-term intrathecal infusion of morphine and morphine/bupivacaine mixtures in the treatment of cancer pain: A retrospective analysis of 51 casesPain, 55
S. Pen, E. Kharasch, A. Williams, Donald Peterson, D. Sloan, Hans Hasche-Klunder, Alexander Krembs (1992)
Chronic epidural bupivacaine-opioid infusion in intractable cancer painPain, 49
JAMA, 29
AbstractBackground and aimsCancer pain treatment has improved over the last decades. The majority of this population can be treated effectively with analgesics following the Guidelines of the original World Health Organisation (WHO). Unfortunately 10–15% of these patients still suffer from severe and refractory cancer pain, especially in the terminal phases of disease and require additional pain management modalities. Therefore, end-stage clinical interventions are particularly needed to minimize the perception of pain. With intrathecal therapy (ITT), drugs are delivered close to their site of action in the central nervous system avoiding first-pass metabolism and blood–brain barrier. It may improve analgesia with a smaller dose and possibly achieve a reduction in systemic or cerebral side effects compared to oral supplied medication alone. Multimodal analgesia enables further dose reduction with improved analgesia and fewer side effects.MethodsIn this retrospective research we investigated the effectiveness and side-effect profile of intrathecal morphine, bupivacaine and clonidine. Patients were followed until death occurred. Pain scores and side effects were recorded before initiating ITT (T0), just after initiating ITT (T1), at hospital discharge (T2), in the ambulant setting (T3) and the last obtained scores before death occurred (T4).ResultsNine patients were included who suffered from severe and refractory cancer pain, not reacting to conventional pain management or had intolerable side effects. Primary tumour location was pancreatic (4), urothelial (3) and prostate (2). Primary pain was considered neuropathic or mixed neuropathic-nociceptive. The treatment team consisted of an anaesthetist, specialized nurse in coordination with primary physician, treating oncologist and specialized home care.All patients were free of pain after initiation of the intrathecal therapy. The average follow-up period was 11 weeks in which there was a slight increase in NRS-score. In the last days before death occurred, half the patients were still free of pain. There were no problems during insertion of the catheter, device malfunction or infection. No severe adverse events defined as hypotension requiring inotropes, respiratory depression or neurological deficits were observed. Three patients experienced mild hypotension which gradually decreased after clonidine dose adjustment. Lower extremity weakness occurred in three patients as well. After bupivacaine dose adjustment the weakness disappeared in two patients and in one patient the lower extremity weakness persisted as a result of conus compression by tumour.Conclusion and implicationsMultimodal IT treatment with morphine, bupivacaine and clonidine is effective and safe for treating refractory cancer pain in the terminal phase of disease.The study offers an important contribution to literature where there is still lack of convincing evidence about the benefits and harms of this type of pain management in patients with otherwise refractory cancer pain.
Scandinavian Journal of Pain – de Gruyter
Published: Jan 1, 2017
Keywords: Intractable cancer pain; Neoplasms; Intrathecal therapy; Multimodal analgesia; Clonidine
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.